Crescent appoints ex-Trinity chief Brendan Farrell CEO
This article was originally published in Clinica
Irish osteoporosis detection specialist Crescent Diagnostics has appointed Brendan Farrell CEO. Mr Farrell most recently headed up EnBio, which specialises in surface modification technology for the medical and non-medical industries; before this, he was president and CEO of Irish diagnostics firm Trinity Biotech from 1994 until 2008. Dublin-based Crescent is developing a test for osteoporosis called BQT that analyses chemical bonds in a small toenail clipping, which has been shown to predict the future risk of hip fracture. The company is about to begin a Series B funding round through which it hopes to raise €5m ($6.6m) to accelerate the commercialisation of BQT. It is currently planning a pivotal study to support CE marking and US FDA approval. Mr Farrell replaces former Crescent CEO Ernest Poku, who left the company due to family commitments.